Journal of Clinical Pediatrics >

2023 , Vol. 41 >Issue 1: 42 - 47

DOI: https://doi.org/10.12372/jcp.2023.22e0415

General Report

Risk factors of hemoptysis volume and postoperative recurrence in children with vascular-related hemoptysis

  • Lei XIE ,
  • Tiewei LYU
Expand
  • Department of Cardiology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China

Received date: 2022-04-18

  Online published: 2023-02-16

Fold

Abstract

Objective To summarize the clinical characteristics of children with vascular-related hemoptysis, in order to find the risk factors of hemoptysis volume and recurrence. Methods The clinical data of children with vascular-related hemoptysis who received interventional therapy from January 2012 to January 2020 were retrospectively analyzed. According to the hemoptysis volume, children were divided into massive hemoptysis group and non-massive hemoptysis group. According to the clinical outcome, they were divided into relapsed group and non-relapsed group. Logistic multivariate regression analysis was used to analyze the factors affecting the hemoptysis volume and the recurrence of postoperative hemoptysis. Results A total of 41 children (19 boys and 22 girls) with vascular-related hemoptysis were included, and the median age was 8.9 (6.9-11.2) years. Chest vascular enhancement CT showed that abnormal blood vessels were located in the right lung in 32 cases, mainly in the lower lobe of the right lung. Abnormal blood vessels were found in both lungs in 3 cases, in the left lung in 1 case, and no abnormal blood vessels were found in 5 cases. Binary logistic regression analysis showed that large abnormal blood vessel diameter and Mycoplasma pneumoniae (MP) infection were independent risk factors for hemoptysis (P<0.05), while increased abnormal blood vessels were independent risk factors for the recurrence of hemoptysis (P<0.05). Conclusions The high risk factors affecting the hemoptysis volume in children with vascular-related hemoptysis are abnormal vascular diameter and MP infection. Interventional occlusion of abnormal blood vessels is a safe and effective treatment method, and the number of abnormal blood vessels is an important predictor of postoperative recurrence.

Key words： hemoptysis; vascular malformation; hemoptysis volume; recurrence; child

Cite this article

Lei XIE , Tiewei LYU . Risk factors of hemoptysis volume and postoperative recurrence in children with vascular-related hemoptysis[J]. Journal of Clinical Pediatrics, 2023 , 41(1) : 42 -47 . DOI: 10.12372/jcp.2023.22e0415

References

[1] Barut K, Sahin S, Adrovic A, et al. Idiopathic pulmonary hemosiderosis in a child with recurrent macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis[J]. Case Rep Pediatr, 2017: 5693501.
[2] Springer DM, Cofta S, Juszkat R, et al. The effectiveness of bronchial artery embolisation in patients with haemoptysis[J]. Adv Respir Med, 2018, 86(5): 220-226.
[3] Rémy J, Voisin C, Dupuis C, et al. Treatment of hemoptysis by embolization of the systemic circulation[J]. Ann Radiol (Paris), 1974, 17(1): 5-16.
[4] Springer DM, Cofta S, Juszkat R, et al. The effectiveness of bronchial artery embolisation in patients with haemoptysis[J]. Adv Respir Med, 2018, 86(5): 220-226.
[5] Zheng Z, Zhuang Z, Yang M, et al. Bronchial artery embolization for hemoptysis: a systematic review and meta-analysis[J]. J Interv Med, 2021, 4(4): 172-180.
[6] Dorji K, Hongsakul K, Jutidamrongphan W, et al. Bronchial artery embolization in life-threatening hemoptysis: outcome and predictive factors[J]. J Belg Soc Radiol, 2021, 105(1): 5.
[7] Fu Z, Li X, Cai F, et al. Microspheres present comparable efficacy and safety profiles compared with polyvinyl alcohol for bronchial artery embolization treatment in hemoptysis patients[J]. J Transl Med, 2021, 19(1): 422.
[8] Kuang HY, Li Q, Xiang P, et al. Potential factors affected safety and efficacy of transcatheter plug closure for pediatric hemoptysis with anomalous bronchial arteries[J]. J Interv Cardiol, 2019: 5408618.
[9] 吕铁伟, 况虹宇, 易岂建, 等. 儿童血管相关性咯血的规范诊断与治疗[J]. 中华实用儿科临床杂志, 2018, 33(13): 979-982.
[10] Chiel L, Welsh S, Andren K, et al. Pediatric hemoptysis without bronchiectasis or cardiac disease: etiology, recurrence, and mortality[J]. J Pediatr, 2019, 214: 66-70.
[11] Dabó H, Gomes R, Marinho A, et al. Bronchial artery embolisation in management of hemoptysis--a retrospective analysis in a tertiary university hospital[J]. Rev Port Pneumol (2006), 2016, 22(1): 34-38.
[12] Abid N, Loukil M, Mokni A, et al. Outcomes of bronchial artery embolization for the management of hemoptysis[J]. Tunis Med, 2021, 99(2): 264-268.
[13] Yang J, Liu F, Liang Y, et al. Massive hemoptysis in children[J]. Can Respir J, 2020: 6414719.
[14] 朱紫阳, 覃伟, 余伟, 等. 支气管扩张症伴咯血的血管介入治疗疗效及其复发相关危险因素分析[J]. 中国介入心脏病学杂志, 2021, 29(5): 266-270.
[15] Bi Y, Zhu Y, Ma X, et al. Development of a scale for early prediction of refractory Mycoplasma pneumoniae pneumonia in hospitalized children[J]. Sci Rep, 2021, 11(1): 6595.
[16] Xiao Z, Jiang Y, Gao X, et al. Comparison of the ameliorative effects of Qingfei Tongluo formula and azithromycin on Mycoplasma pneumoniae pneumonia[J]. J Nat Med, 2017, 71(4): 685-692.
[17] Fruchter O, Schneer S, Rusanov V, et al. Bronchial artery embolization for massive hemoptysis: long-term follow-up[J]. Asian Cardiovasc Thorac Ann, 2015, 23(1): 55-60.
[18] Yan HT, Lu GD, Huang XZ, et al. Development of a model to predict recurrence after bronchial artery embolization for non-cancer related hemoptysis[J]. BMC Pulm Med, 2021, 21(1): 419.
[19] Tom LM, Palevsky HI, Holsclaw DS, et al. Recurrent bleeding, survival, and longitudinal pulmonary function following bronchial artery embolization for hemoptysis in a U.S. adult population[J]. J Vasc Interv Radiol, 2015, 26(12): 1806-1813.
[20] Merida-Vieyra J, Aquino-Andrade A, Palacios-Reyes D, et al. Detection of Mycoplasma pneumoniae in Mexican children with community-acquired pneumonia: experience in a tertiary care hospital[J]. Infect Drug Resist, 2019, 12: 925-935.
[21] Krafft C, Christy C. Mycoplasma pneumonia in children and adolescents[J]. Pediatr Rev, 2020, 41(1): 12-19.
[22] He J, Liu M, Ye Z, et al. Insights into the pathogenesis of Mycoplasma pneumoniae (Review)[J]. Mol Med Rep, 2016, 14(5): 4030-4036.
[23] Miyata M, Hamaguchi T. Integrated information and prospects for gliding mechanism of the pathogenic bacterium Mycoplasma pneumoniae[J]. Front Microbiol, 2016, 7: 960.
Options
Outlines

/

〈 〉

Website Copyright © 2018 Journal of Clinical Pediatrics.
Tel: 021-25076489　E-mail: jcperke@126.com
Powered by Beijing Magtech Co. Ltd